Next Article in Journal
Systemic Sclerosis: From Pathophysiology to Novel Therapeutic Approaches
Next Article in Special Issue
Novel Biomarkers Detected by Proteomics Predict Death and Cardiovascular Events in Hemodialysis Patients
Previous Article in Journal
From NAFLD to MAFLD: Aligning Translational In Vitro Research to Clinical Insights
Review

Recent Developments in Clinical Plasma Proteomics—Applied to Cardiovascular Research

1
Centre for Clinical Proteomics, Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, 5000 Odense, Denmark
2
Computational and Experimental Biology Group, CEDOC, Chronic Diseases Research Centre, NOVA Medical School, Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, 1169-056 Lisbon, Portugal
*
Author to whom correspondence should be addressed.
Academic Editor: Estefania Nuñez
Biomedicines 2022, 10(1), 162; https://doi.org/10.3390/biomedicines10010162
Received: 16 December 2021 / Revised: 5 January 2022 / Accepted: 12 January 2022 / Published: 12 January 2022
(This article belongs to the Special Issue Proteomics in Cardiovascular Disease)
The human plasma proteome mirrors the physiological state of the cardiovascular system, a fact that has been used to analyze plasma biomarkers in routine analysis for the diagnosis and monitoring of cardiovascular diseases for decades. These biomarkers address, however, only a very limited subset of cardiovascular diseases, such as acute myocardial infarct or acute deep vein thrombosis, and clinical plasma biomarkers for the diagnosis and stratification cardiovascular diseases that are growing in incidence, such as heart failure and abdominal aortic aneurysm, do not exist and are urgently needed. The discovery of novel biomarkers in plasma has been hindered by the complexity of the human plasma proteome that again transforms into an extreme analytical complexity when it comes to the discovery of novel plasma biomarkers. This complexity is, however, addressed by recent achievements in technologies for analyzing the human plasma proteome, thereby facilitating the possibility for novel biomarker discoveries. The aims of this article is to provide an overview of the recent achievements in technologies for proteomic analysis of the human plasma proteome and their applications in cardiovascular medicine. View Full-Text
Keywords: mass spectrometry-based proteomics; affinity proteomics; cardiovascular disease; plasma proteomics mass spectrometry-based proteomics; affinity proteomics; cardiovascular disease; plasma proteomics
Show Figures

Figure 1

MDPI and ACS Style

Palstrøm, N.B.; Matthiesen, R.; Rasmussen, L.M.; Beck, H.C. Recent Developments in Clinical Plasma Proteomics—Applied to Cardiovascular Research. Biomedicines 2022, 10, 162. https://doi.org/10.3390/biomedicines10010162

AMA Style

Palstrøm NB, Matthiesen R, Rasmussen LM, Beck HC. Recent Developments in Clinical Plasma Proteomics—Applied to Cardiovascular Research. Biomedicines. 2022; 10(1):162. https://doi.org/10.3390/biomedicines10010162

Chicago/Turabian Style

Palstrøm, Nicolai B., Rune Matthiesen, Lars M. Rasmussen, and Hans C. Beck. 2022. "Recent Developments in Clinical Plasma Proteomics—Applied to Cardiovascular Research" Biomedicines 10, no. 1: 162. https://doi.org/10.3390/biomedicines10010162

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop